# Pre-Read Brief (Egypt Obesity Burden Study)

Before you start the questions, read the **“The Burden of Obesity in Egypt”** paper with a policy lens. You don’t need to memorize tables—focus on the logic: what the authors measured, how they measured it, and what that means for decision-making.

**Mindset:** Imagine you’re advising the Ministry of Health. As you read, keep asking: *If this evidence is true, what should we prioritize next?*

## How the assessment will mirror your reading

* **Recall:** core definitions, study objective, broad outcomes used (e.g., health loss measures, cost categories).
* **Methods understanding:** how burden was estimated, key inputs and assumptions, what’s included/excluded.
* **Policy interpretation:** what the findings imply for prioritization, feasibility, and trade-offs.

---

# Pre-Read Guide (Use while you read)

| Section of Study              | What to Focus On                                                                                                                                                                   | Questions to Ask Yourself                                                                                    |
| ----------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------ |
| **Title   Abstract**          | One-sentence purpose, approach, and headline finding (directionally, not numbers).                                                                                                 | *What is the study about in one sentence?* *What outcomes did they report?*                                  |
| **Introduction / Background** | Why the topic matters locally (scale, trends, health system impact).                                                                                                               | *Why is this important for Egypt right now?* *What policy pain points does it speak to?*                     |
| **Methods**                   | The burden-estimation approach (e.g., how exposure and risks translate to outcomes), data sources, perspective, time frame, what costs are counted vs. not, and major assumptions. | *What’s the model/estimation logic?* *Which inputs drive results most?* *What did they leave out (and why)?* |
| **Outcomes   Measures**       | How health loss and costs are defined and reported; how comparators or categories are structured.                                                                                  | *Which outcomes are used (and why these)?* *Are they appropriate for policy decisions?*                      |
| **Results**                   | Patterns, not numbers: which disease areas, age/sex groups, or settings appear to carry more burden; how costs and health loss cluster.                                            | *Where does the burden concentrate?* *What themes would matter for budgeting and planning?*                  |
| **Discussion**                | Interpretation for policy; what authors think should happen; realism/feasibility in Egypt; potential levers (prevention, clinical management, financing).                          | *If I had to recommend three actions, what would they be and why?*                                           |
| **Limitations**               | Data gaps, assumptions, generalizability, potential over/under-estimation, perspective constraints.                                                                                | *How confident should a policymaker be?* *What would I want to validate before acting?*                      |
| **Conclusion / Implications** | The core takeaway and next steps for policy and research.                                                                                                                          | *What is the single most actionable insight for MOH?*                                                        |

---

## Self-Check (no spoilers)

By the end of the pre-read, you should be able to answer—**without** quoting numbers:

1. **Main question:** What did the authors try to quantify and why does it matter for Egypt?
2. **Approach:** In plain language, how did they translate exposure/risk and costs into a national burden estimate? What was included vs. excluded?
3. **Signal in results:** Where does the burden *tend* to be concentrated (diseases, groups, settings) and why that matters for policy?
4. **Policy angle:** Given these patterns, what are two or three feasible first moves (and what assumptions would you test before scaling)?
5. **Caveats:** Which limitations would you flag when presenting this to leadership?

---

## Reading Tips

- **Skim first, then zoom:** Abstract → figures/tables captions → Methods → Discussion.
- **Mark assumptions:** Circle any assumption that, if wrong, would change the conclusion.
- **Think trade-offs:** Note at least one quick-win policy and one longer-term structural lever.
---

# Budget Impact vs Cost-Effectiveness Analysis

### Purpose   Questions Addressed
- **Cost-Effectiveness (CEA):** How to allocate resources efficiently for maximum health gain relative to cost; compares a new treatment to the standard of care over the long term to judge **value for money**.
- **Budget Impact Analysis (BIA):** Can the system **afford** adoption within existing budget constraints; supports short-term financial planning to avoid overspending.

### Shared Assumptions / Models
Both may rely on the same clinical inputs (e.g., “Medicine B reduces complications by 20% and improves response by 15%”) and can use similar structures (decision trees, Markov models) to simulate outcomes.

### Key Differences
 u **Time Horizons** /u  br 

-  **CEA:** Long-term, often lifetime, to capture all costs and outcomes.
- **BIA:** 3–5 years to match budgeting cycles.
 u **Cohort Structure** /u 
  br 
-  **CEA:** *Closed* cohort (fixed group followed over time).  
-   **BIA:** *Open* cohort (new eligible patients can enter each year).

 u **Complexity / Model Structure** /u    br 
- **BIA** often more complex due to incidence/prevalence, subgroup epidemiology, and current vs. forecasted market shares.
 u **Comparators** /u    br 
- **CEA:** New treatment vs. **standard of care**.  
- **BIA:** New treatment vs. a **mix** of existing options reflecting real-world substitution.
 br 
 u **Additional Data for BIA** /u  br 
Eligible population sizes, incidence   prevalence, subgroup splits, **current and forecasted market shares**, and forecasting methods to estimate spend over the time horizon.

---

## Quick Comparison Table (optional)

| Aspect                | CEA (Cost-Effectiveness)                | BIA (Budget Impact)                             |
|----------------------|------------------------------------------|-------------------------------------------------|
| Primary question     | Efficiency / value for money             | Affordability / budget fit                      |
| Time horizon         | Long-term, often lifetime                | 3–5 years                                       |
| Cohort               | Closed (no new entrants)                 | Open (new entrants over time)                   |
| Comparator(s)        | Standard of care                         | Mix of existing therapies                       |
| Extra data needs     | Standard clinical/economic inputs        | Incidence, prevalence, subgroups, market shares, forecasts |
| Typical use          | Reimbursement / value decision           | Annual / medium-term financial planning         |
 br 
 br 
*Short article by Prof. Dr. Lieven Annemans*

# Case Study: Application of Nation-Wide Exponential Price–Volume Agreements in Italy for Innovative Drugs

## Introduction / Background
The pharmaceutical industry often develops highly innovative and effective drugs designed for large patient populations. While these drugs offer significant clinical value, their high prices pose a substantial challenge to healthcare systems globally, leading to immense and often unsustainable budgetary impacts—even for the wealthiest countries—when treating all eligible patients. This issue has prompted the need for new pricing methods that can reduce drug prices compared to standard **value-based** approaches, yet remain acceptable for drug companies.

---

## The Challenge
For drugs like **sofosbuvir** (hepatitis C) and **PCSK9 inhibitors** (high cholesterol), the potential patient population is so large that even prices determined by a *value-based* approach would lead to an unsustainable budget impact. For instance, PCSK9 inhibitors could potentially treat up to **2.6 million** people in the USA. The “traditional” value-based prices for these drugs (e.g., **US$3,166–7,735** per patient per year for PCSK9 inhibitors) were deemed too high due to the sheer volume of patients, making the overall budget impact unsustainable. This necessitated innovative approaches to price reduction beyond traditional value-based pricing.

---

## The Solution: Nation-Wide Exponential Price–Volume Agreements
One significant solution developed—particularly for the Italian market—is the nation-wide **price–volume agreement**. This approach dictates that drug prices are progressively reduced as more patients receive the treatment. Unlike historical price–volume agreements that were applied on an empirical basis, more recently, explicit mathematical models have been described and evaluated through real-world experiences, especially in Italy. This method plays a crucial role in promoting the sustainability of critical treatments.

---

## Mechanism and Key Parameters
The core of this method relies on an **exponential price–volume relationship**, where the price undergoes a progressive decay as the number of treated patients increases. A fundamental parameter of this model is the **Price Halving Population (PHP)**. According to the PHP, the treatment price is **halved** every time the number of treated patients increases by a volume equal to PHP.

---

## Real-World Application in Italy (Case Examples)
- **Ranibizumab:** Prices halved for every **41,878** treated patients (expected population **20,000**). Estimated average price to treat 20,000 patients: **€7,705**.  
- **Sofosbuvir:** Prices halved for every **18,579** treated patients (expected population **60,000**). Estimated average price to treat 60,000 patients: **€14,969**.  
- **PCSK9 inhibitors** (*evolocumab, alirocumab*): Prices halved for every **25,000** treated patients (expected populations **50,000** or **100,000**). Estimated average price to treat **100,000** patients: **€3,382** (or **€5,411** for 50,000). Treatment cost per patient per year reduced to ** €626** when ** 100,000** patients were treated.

*These analyses for ranibizumab and sofosbuvir have already led to specific nation-wide reimbursement decisions by the Italian Drug Agency (AIFA).*

---

## Impact and Rationale for Differentiated Price Decay
The values of **PHP** can differ across drugs, allowing individualized price decisions based on drug characteristics. A crucial factor influencing the price–volume relationship is the **Nation-wide Budget Impact (NwBI)**. As **NwBI** increases, prices are compelled to decline more quickly.

This explains why Italian decision-makers empirically established a more rapid price decay for **sofosbuvir** than for **ranibizumab** (*price decay = gradual reduction in price after launch*). The sustainability of sofosbuvir was deemed more critical due to its significantly higher yearly **NwBI** and larger potential patient population:

- **Ranibizumab (20,000 patients):** NwBI = **€181 million** (average price **€7,705**).  
- **Sofosbuvir (60,000 patients):** NwBI = **€2,250 million** (average price **€14,969**).

Thus, drugs with a very strong budget impact like **sofosbuvir** require a more aggressive policy of rapid price decay in the price–volume relationship, whereas less critical drugs like **ranibizumab** can have a less aggressive decay.

---

## Strengths of the Approach
- **Sustainability:** Promotes affordability of expensive, critical treatments via progressive price reductions.  
- **Rational Framework:** Moves beyond empirical deals toward a more **theoretical and practical** structure for price–volume agreements.  
- **Flexibility:** Allows individualized price decisions based on drug characteristics and budget impact.  
- **Real-World Validation:** For ranibizumab and sofosbuvir, experimental data fit the models, showing practical applicability.

---

## Limitations of the Approach
- **Country Specificity:** PHP and NwBI depend on population size; adapting to other countries requires recalibration.  
- **Complexity:** Operational terms of the “new math” can be complex.  
- **Data Availability:** Information can be scarce; many local agreements are confidential.  
- **Perspective:** Primarily payer-focused; industry perspectives are not explicitly modeled.  
- **Predictive Uncertainty:** Limited examples prevent firm conclusions on the “appropriate” PHP value.
 br 
**Reference** br 

Messori, Andrea.“Application of the Price–Volume Approach in Cases of Innovative Drugs Where Value-
Based Pricing Is Inadequate: Description of Real Experiences in Italy.” Clinical Drug Investigation, vol. 36,
no. 8, 23 May 2016, pp. 599–603, https://doi.org/10.1007/s40261-016-0408-9. Accessed 4 July 2025. br 

# Japan’s CA Program: A Case of Conditional Evidence and Early Access

Japan's **Challenge Application (CA)** program, introduced in April 2018 by the **Ministry of Health, Labour and Welfare (MHLW)**, serves as a direct example of a **Coverage with Evidence Development (CED)** program. The CA program was established to address the challenge of lack of robust clinical evidence in the early stages of a new medical technology's introduction.

---

## Purpose and Operational Characteristics

The CA program was developed to: br 

- **Overcome the barrier of insufficient evidence:** It provides a mechanism for verifying the final assessment of coverage determinations for long-term implantable technologies or highly innovative medical technologies that initially lack appropriate clinical evidence.
- **Enable earlier patient access:** By allowing technologies to be listed for coverage and reimbursement **conditionally**, it provides an opportunity for patients to access new technologies sooner.
- **Incentivize evidence generation:** It offers the potential for premium prices if manufacturers can prove the clinical value of their technologies through additional **post-market** evidence.

---

## Key Operational Features

- **Applicant:** Manufacturers or distributors of medical technologies are the sole applicants for the CA program. They must submit a plan for clinical data collection and evaluation.
- **Target Technologies:** Primarily **Special Treatment Materials (STMs)**—specific functional categories such as coronary stents and pacemakers.
- **Governance and Approval:** Designed through expert panel discussions on STMs; findings/recommendations are approved by the **Central Social Insurance Medical Council (CSIMC / Chuikyo)**, an advisory body to the MHLW.
- **Evidence Generation:** Manufacturers are responsible for generating and collecting evidence. If accepted, applicants must submit periodic reports at least every two years using **Form 15**.
- **Reevaluation:** After granting CA eligibility, reevaluation follows a process similar to a **C1** category application (regardless of the initial category). The reevaluation period depends on the protocol.
- **Patient Financial Burden:** Patient copayment rates are relatively low—**around 30%**.
- **Expected Administrative Measures:** After successful reevaluation, the MHLW can create new functional categories and adjust premium pricing. Although a premium can be sought post-market, the likelihood of a ** 3–5%** premium above conventional technologies has been decreasing.
- **Withdrawal:** Manufacturers may request withdrawal (e.g., difficulty collecting data) by providing a legitimate reason.

---

## Case Study: Pacemaker with Enhanced Functionality

- **Initial Application:** The manufacturer applied for coverage in 2007 and 2012 (next-generation, MRI-compatible). New functional categories with utility premiums were granted, but the **reactive anti-tachycardia pacing (rATP)** algorithm’s value was not fully assessed due to limited evidence.
- **New Evidence:** Clinical evidence published in 2014 and additional studies showing that atrial fibrillation (AF) progression increases the risks of stroke and heart failure supported reevaluation.
- **CA Application:** In June 2019, after the CA program’s introduction, the manufacturer requested reevaluation of the rATP algorithm using the new evidence.
- **Outcome:** The manufacturer demonstrated that rATP reduced strokes and heart-failure episodes by suppressing AF progression. The MHLW recognized the improvement, created a new functional category, and provided a **3% premium price (2019)**.

---

## Opportunities for Improvement

While the CA program enables earlier access and offers incentives—especially compared to **South Korea’s CSB** (e.g., **80%** copayment for TAVR):

- **Stakeholder Collaboration:** Unlike US CED programs (e.g., **TAVR registry**) that involve manufacturers, government, professional societies, and patient organizations from early stages, Japan’s CA places responsibility for evidence solely on manufacturers. No official registry requirements exist to date.
- **Transparency:** Limited transparency around internal decision-making makes it difficult for applicants to understand success/failure factors.
- **Premium Pricing:** Although premium pricing is allowed, the realized premium (e.g., **3–5%**) may not strongly incentivize highly innovative technologies—and this percentage has been decreasing.

*Japan can strengthen CED by drawing on US practices—earlier multi-stakeholder engagement, formal registries, and clearer decision transparency.*

---

## Reference

Myung JE, Tanaka Y, Choi H, Strachan L, Watanuki T, Lee JH, Hwang H, Lee SS. **Coverage with Evidence Development Programs for Medical Technologies in Asia-Pacific Regions: A Case Study of Japan and South Korea.** *JMA Journal.* 2021;4(4):311–320. doi: **10.31662/jmaj.2021-0011**. Epub 2021 Sep 13. PMID: **34796285**; PMCID: **PMC8580702**. br 
 br 

## Get Ready for Your Assessment
Before you dive into the questions, read the attached **cost-utility** study (Markov model) carefully—ideally twice—*before* attempting the quiz. Think of this as your roadmap: do one pass, then use this guide to re-read with purpose.

---

## How the assessment will mirror your reading
- **Recall:** e.g., *What was the comparator?*
- **Model understanding:** e.g., *How many health states?*
- **Policy thinking:** e.g., *Interpreting ICERs for decisions*

**If you can answer:**
1) **What was the main question?**  
2) **How was the model built?**  
3) **What did the results show?**  
—you’re ready to ace the test.

---

## How to Read the Study

### Abstract
**Focus on:** Objective, methods (Markov model), key result (ICER, QALYs), conclusion  
**Ask:** *What’s the study about in one sentence?*

### Introduction
**Focus on:** Why obesity is a problem in Saudi Arabia, why bariatric surgery matters  
**Ask:** *Why is this study important in the Saudi context?*

### Methods
**Focus on:** Health states in the Markov model, cycle length, **perspective** (societal vs healthcare), comparator (**liraglutide + lifestyle**)  
**Ask:** *How did they design the model to compare surgery vs standard care?*

### Results
**Focus on:** Incremental QALYs, incremental costs, **ICER** values, thresholds 
**Ask:** *Which option was more cost-effective, and under what threshold?*

### Discussion
**Focus on:** Interpretation of results, **sensitivity analysis** (what changes ICER most), barriers (insurance, waiting times)  
**Ask:** *What do these results mean for policymakers?*

### Conclusion
**Focus on:** Main takeaway (*is bariatric surgery cost-effective?*)  
**Ask:** *If I were at the Ministry of Health, what decision would I make based on this?*

---

## Stuck on something?
If anything is unclear, head to the **discussion forums** to ask questions, share thoughts, and clarify ideas. You can tag the instructors directly for input and guidance.